Yakult Central Institute for Microbiological Research, Tokyo, Japan.
Immunology. 2009 Sep;128(1 Suppl):e170-80. doi: 10.1111/j.1365-2567.2008.02942.x. Epub 2008 Oct 15.
Interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signals play key roles in the pathogenesis of inflammatory bowel disease (IBD). We previously described that both intact cells and a cell wall-derived polysaccharide-peptidoglycan complex (PSPG) in a strain of lactobacillus [Lactobacillus casei Shirota (LcS)] inhibited IL-6 production in lipopolysaccharide (LPS)-stimulated lamina propria mononuclear cells (LPMCs) isolated from murine IBD. Diets with LcS improve murine IBD by suppression of IL-6 synthesis in LPMCs. Moreover, LcS supplementation with fermented milk ameliorates disease activity in patients with active ulcerative colitis. Here, we focused on the specific roles of PSPG in LcS concerning their anti-inflammatory actions. PSPG derived from LcS, and no other strain of lactobacilli, inhibited IL-6 production in LPS-stimulated murine IBD LPMCs. Purified PSPG-I from LcS inhibited IL-6 synthesis in LPS-stimulated murine IBD LPMCs through the inhibition of nuclear factor-kappaB. The anti-IL-6 action of LcS PSPG was abrogated by masking with monoclonal anti-PSPG-I. Furthermore, PSPG-I-negative L. casei strains (PSPG-I-negative mutant LcS: LC(DeltaPSPG-I), L. casei ATCC 334) did not inhibit IL-6 production. Finally, we confirmed the effects of PSPG-I on LcS in the models of both IBD and colitis-associated cancer (CAC). In the IBD model, ingestion of LcS improved ileitis and inhibited activation of IL-6/STAT3 signaling, while ingestion of the LC(DeltaPSPG-I) strain did not. In the CAC model, treatment with LcS, but not the LC(DeltaPSPG-I) strain, showed tumour-suppressive effects with an inhibition of IL-6 production in the colonic mucosa. These results suggested that a specific polysaccharide component in an L. casei strain plays a crucial role in its anti-inflammatory actions in chronic intestinal inflammatory disorders.
白细胞介素-6(IL-6)/信号转导和转录激活因子 3(STAT3)信号在炎症性肠病(IBD)的发病机制中起关键作用。我们之前描述过,在一株乳酸杆菌[干酪乳杆菌 Shirota(LcS)]中,完整细胞和细胞壁衍生的多糖-肽聚糖复合物(PSPG)均抑制脂多糖(LPS)刺激的来自鼠 IBD 的粘膜固有层单核细胞(LPMCs)中 IL-6 的产生。含有 LcS 的饮食通过抑制 LPMCs 中 IL-6 的合成来改善鼠 IBD。此外,LcS 与发酵乳的补充可改善活动期溃疡性结肠炎患者的疾病活动度。在这里,我们专注于 PSPG 在 LcS 中的抗炎作用的特定作用。源自 LcS 的 PSPG,而不是其他的乳杆菌菌株,抑制 LPS 刺激的鼠 IBD LPMCs 中 IL-6 的产生。来自 LcS 的纯化 PSPG-I 通过抑制核因子-κB 抑制 LPS 刺激的鼠 IBD LPMCs 中 IL-6 的合成。LcS PSPG 的抗 IL-6 作用通过与单克隆抗 PSPG-I 掩蔽而被消除。此外,PSPG-I 阴性的干酪乳杆菌菌株(PSPG-I 阴性突变 LcS:LC(DeltaPSPG-I),干酪乳杆菌 ATCC 334)不抑制 IL-6 的产生。最后,我们在 IBD 和结肠炎相关癌症(CAC)模型中证实了 PSPG-I 对 LcS 的作用。在 IBD 模型中,摄入 LcS 可改善回肠炎并抑制 IL-6/STAT3 信号的激活,而摄入 LC(DeltaPSPG-I)菌株则没有。在 CAC 模型中,LcS 的治疗作用,但不是 LC(DeltaPSPG-I)菌株,显示出肿瘤抑制作用,抑制结肠黏膜中 IL-6 的产生。这些结果表明,乳杆菌菌株中的特定多糖成分在其慢性肠道炎症性疾病中的抗炎作用中起着关键作用。